Crossmark

A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab

Crossref DOI link: https://doi.org/10.1038/eye.2017.67

Published Online: 2017-05-05

Published Print: 2017-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rufai, S R

Almuhtaseb, H

Paul, R M

Stuart, B L

Kendrick, T

Lee, H

Lotery, A J
License Information

Text and Data Mining valid from 2017-05-05
More Information

Article History

Received: 24 December 2016

Accepted: 12 March 2017

First Online: 5 May 2017

Competing interests

: SRR, HA and AJL have been supported by travel grants from Bayer. The remaining authors declare no conflict of interests.